EnteroMedics Announces Presentations at ObesityWeek 2017

EnteroMedics Announces Presentations at ObesityWeek 2017

ST. PAUL, Minn., Oct. 16, 2017 /PRNewswire/ — EnteroMedics Inc. (NASDAQ:ETRM), a developer of minimally invasive medical devices to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that the Company and its products will be the subjects of two oral presentations and one poster presentation at ObesityWeek 2017, taking place in Washington, D.C. from October 29, 2017 to November 2, 2017.

The presentations will feature:

  • vBloc® Real-World Patient Data
  • ReShape®  Integrated Dual Balloon System Patient Data
  • Gastric Vest™ System Initial Clinical Results

Details of the presentations are as follows:

Tuesday, October 31, 2017: 2:13PM ET: Poster Presentation

Presentation Title:       

A5292 Short-Term Results for Intermittent Vagal Nerve Blocking (vBloc) in the “Real-World”, Non-Research Environment


Scott Shikora, M.D., F.A.C.S., F.A.S.M.B.S., Professor of Surgery at Harvard Medical School; Director of the Center for Metabolic and Bariatric Surgery at Brigham and Women’s Hospital

Thursday, November 2, 2017: Podium Presentations


Maryland A, Ballroom Level



2:14PM ET

Presentation Title:       

A149 Intragastric Balloon: 342 Patients Treated at a Multicenter Bariatric Practice


Shawn Garber, M.D., FACS FASMBS, New York Bariatric Group

2:36PM ET

Presentation Title:       

A151 Gastric Vest System: Initial Results of a Novel Restrictive Bariatric Procedure


Juan Antonio Lopez-Corvala, M.D., Professor of Surgery, Medical Faculty of the Autonomous University of Baja California; Leader in Bariatric Surgery Program, Hospital Ángeles Tijuana.

For more details on ObesityWeek 2017, please visit https://obesityweek.com.

About EnteroMedics Inc.
EnteroMedics is a medical device company focused on the development and commercialization of technology to treat obesity and metabolic diseases. vBloc® Neurometabolic Therapy, delivered by an FDA-approved pacemaker-like device called the vBloc System, is designed to help patients feel full and eat less by intermittently blocking hunger signals on the vagus nerve. The Company’s ReShape® Integrated Dual Balloon System involves a non-surgical weight loss procedure that uses advanced balloon technology designed to help people with a 30-40 Body Mass Index (BMI), and at least one co-morbidity, lose weight. The ReShapeProcedure was approved by the U.S. Food and Drug Administration in July of 2015 and has been available in Europe since 2011. The Gastric VestTM System (GVS) is an investigational, minimally invasive, laparoscopically implanted medical device being studied for weight loss in obese and morbidly obese patients. The device wraps around the stomach, emulating the effect of conventional weight-loss surgery, and is intended to enable gastric volume reduction without permanently changing patient anatomy.  EnteroMedics acquired the Gastric Vest System through its acquisition of BarioSurg, Inc. in May 2017 and the ReShape Dual Intragastric Balloon through its acquisition of ReShape Medical in October 2017.

Forward-Looking Safe Harbor Statement:

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by the use of words such as expect,” “plan,” “anticipate,” “could,” “may,” “intend,” “will,” “continue,” “future,” other words of similar meaning and the use of future dates. These forward-looking statements are based on the current expectations of our management and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others: our limited history of operations; our losses since inception and for the foreseeable future; our limited commercial sales experience with our vBloc® System for the treatment of obesity in the United States or in any foreign market other than Australia and the European Community; the competitive industry in which we operate; our ability to maintain compliance with the Nasdaq continued listing requirements; our ability to commercialize our vBloc System; our dependence on third parties to initiate and perform our clinical trials; the need to obtain regulatory approval for any modifications to our vBloc System; physician adoption of our vBloc System and vBloc Neurometabolic Therapy; our ability to obtain third party coding, coverage or payment levels; ongoing regulatory compliance; our dependence on third party manufacturers and suppliers; the successful development of our sales and marketing capabilities; our ability to raise additional capital when needed; international commercialization and operation; our ability to attract and retain management and other personnel and to manage our growth effectively; potential product liability claims; the cost and management time of operating a public company; potential healthcare fraud and abuse claims; healthcare legislative reform; and our ability to obtain and maintain intellectual property protection for our technology and products. These and additional risks and uncertainties are described more fully in the Company’s filings with the Securities and Exchange Commission, particularly those factors identified as “risk factors” in Exhibit 99.3 of our current report on Form 8-K filed July 26, 2017. We are providing this information as of the date of this press release and do not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise.